Search results
Horizon Therapeutics is a company that develops and commercializes medicines for rare diseases. It was acquired by Amgen in 2023 and has offices around the world.
Horizon Therapeutics was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. [4]
Oct 6, 2023 · Amgen announces the closing of its $27.8 billion deal to buy Horizon, a biotech company with rare disease medicines. The acquisition strengthens Amgen's inflammation portfolio and expands its global presence and revenue growth.
Oct 6, 2023 · Oct 6 (Reuters) - Amgen (AMGN.O) said on Friday it had completed the $27.8 billion acquisition of Horizon Therapeutics (HZNP.O) after it received the go-ahead from the U.S. Federal Trade ...
People also ask
What happened to Horizon Therapeutics plc?
Where is Horizon Therapeutics HQ?
What does Horizon Therapeutics do?
Did Amgen buy Horizon Therapeutics?
Sep 1, 2023 · WASHINGTON—The Federal Trade Commission said Friday it had agreed to end its legal challenge of drugmaker Amgen ’s AMGN -0.75% $27.8 billion deal to buy Horizon Therapeutics, averting a trial...
Mar 1, 2023 · Fourth-Quarter 2022 Results: -- Net Sales of $942.0 Million -- -- GAAP Net Income of $120.4 Million; Adjusted EBITDA of $357.5 Million; Includes $37.3 Million of Acquired IPR&D and Milestones ...
Dec 12, 2022 · Amgen will acquire Horizon, a biopharmaceutical company that focuses on treatments for rare, autoimmune diseases, in a deal valued at approximately $26.4 billion. Horizon’s best-seller, Tepezza, is only approved in the United States and treats eye bulging and double vision from thyroid eye disease.
